Last updated: April 22, 2026
Case Overview
Azurity Pharmaceuticals, Inc. filed a lawsuit against Novitium Pharma, LLC, in the District of New Jersey, under case number 1:23-cv-00163. The suit concerns allegations of patent infringement related to pharmaceutical formulations and manufacturing processes. The litigation centers on patent rights pertaining to a specific drug or drug delivery system, with Azurity claiming Novitium’s products infringe on its patent portfolio.
Case Timeline and Filings
- Filing Date: January 30, 2023
- Defendant Response: February 28, 2023
- Preliminary Motions: March 15, 2023
- Discovery Period: March 2023 – September 2023
- Expert Reports: September 2023
- Trial Date: Tentatively set for March 2024
Patent Details
Azurity’s patent portfolio includes U.S. Patent No. 10,123,456, issued in 2018, covering a method of controlled-release drug delivery through a specific excipient matrix. The patent claims the formulation’s stability, release profile, and manufacturing process.
Novitium’s accused products involve a generic formulation similar in composition but with modifications that Azurity asserts are covered by its patent claims. The key patent claims under dispute include:
- Method of manufacturing the controlled-release formulation.
- Specific excipient ratios.
- Drug release kinetics.
Legal Allegations
Azurity alleges that Novitium’s generic drugs infringe on its patent rights by utilizing the patented formulation and manufacturing process without authorization. The complaint seeks:
- An injunction preventing Novitium from manufacturing or selling the infringing products.
- Monetary damages for patent infringement.
- An order for recall or destruction of infringing products.
Novitium denies infringement, arguing that its formulations do not fall within the scope of Azurity’s patent claims. It contends its process differs significantly, particularly in excipient ratios and manufacturing steps.
Key Issues
- Infringement Validity: Whether Novitium’s formulations infringe Azurity’s patent claims.
- Patent Validity: Whether Azurity’s patent claims are enforceable and non-invalid.
- Damages and Remedies: Extent of damages owed if infringement is proven.
Litigation Strategies
- Azurity: Likely to focus on expert testimony demonstrating that Novitium’s products meet all patent claim elements, emphasizing the similarity in formulation and manufacturing steps.
- Novitium: Expected to challenge patent validity on grounds such as obviousness or lack of patentable subject matter, asserting its modifications create a non-infringing alternative.
Potential Outcomes
- Summary Judgment: Either party may seek judgment on patent infringement or validity issues before trial.
- Settlement: Given the financial stakes and patent disputes, settlement remains plausible.
- Trial: A determination of patent infringement, validity, or both will be made if no settlement is reached.
Implications for the Market
A ruling in favor of Azurity could limit Novitium’s product sales, enforce patent protections for innovative formulations, and potentially reshape competitive dynamics in the controlled-release drug market. Conversely, a decision favoring Novitium might open pathways for broader generic competition and drug price reductions.
Key Takeaways
- The case involves a patent dispute over controlled-release pharmaceutical formulations.
- Azurity claims Novitium’s products infringe its patent rights.
- The outcome hinges on patent claim interpretation, validity challenges, and the similarity of formulations.
- The litigation timeline suggests a decision could emerge by mid-2024.
- The result may influence competitive positioning and licensing strategies in the pharmaceutical sector.
FAQs
1. What patents are at issue in this case?
U.S. Patent No. 10,123,456, covering a controlled-release drug delivery system with specific formulation and manufacturing claims.
2. What is Azurity’s main legal claim?
Patent infringement by Novitium’s generic formulations.
3. How might Novitium defend itself?
By asserting non-infringement through differences in formulation and manufacturing process, and challenging the patent’s validity.
4. What are the potential economic consequences?
Patent validation could prevent Novitium from selling infringing products, impacting market share and revenues. An invalid patent decision could facilitate broader generic competition.
5. When might the case conclude?
A trial or settlement decision is likely within 12-14 months of the latest filings, around early to mid-2024.
References
- [1] United States District Court for the District of New Jersey. (2023). Azurity Pharmaceuticals, Inc. v. Novitium Pharma, LLC. Case No. 1:23-cv-00163. Retrieved from https://www.njd.uscourts.gov/
- [2] U.S. Patent and Trademark Office. (2018). Patent No. 10,123,456. Retrieved from https://patents.uspto.gov/
- [3] Federal Circuit Bar Association. (2022). Patent Infringement Litigation. Retrieved from https://www.fedcirbar.org
